Author Archives: Marisa Wexler MS

The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD). The approved trial design will be a double-blinded, placebo-controlled, phase 1/2 trial to assess the…

In people with chronic obstructive pulmonary disease (COPD) who experience acute exacerbations, the use of amoxicillin alone is associated with better outcomes than treatment with amoxicillin in combination with clavulanic acid, another antibiotic, a Danish study shows. The study, “Antibiotic treatment in acute exacerbation of COPD:…

Inhibiting a protein called lymphotoxin beta receptor (LTβR) could be an effective therapeutic strategy for chronic obstructive pulmonary disease (COPD), new research suggests. The findings were published in Nature, in the study “Inhibition of LTβR signalling activates WNT-induced regeneration in lung.” COPD is characterized by the…

Health Care Service Corporation (HCSC) has issued a positive coverage policy for Pulmonx’s Zephyr Endobronchial Valve for treating severe emphysema, a form of chronic obstructive pulmonary disease (COPD). HCSC is the largest customer-owned health insurer in the U.S., and the fifth largest insurer…

The U.S. Food and Drug Administration has granted clearance to PulmoScan, a device developed by Cognita Labs that will facilitate at-home testing of lung function. The device could be useful in providing care to people with respiratory conditions such as asthma and chronic obstructive pulmonary disease…

The first participant has been treated in a clinical trial testing CSA Medical’s RejuvenAir System as a potential treatment for people with moderate to severe chronic obstructive pulmonary disease (COPD) with chronic bronchitis. The participant was treated at Temple University Hospital. At present, the multicenter international…

A committee from the European Medicines Agency (EMA) recommended that AstraZeneca‘s triple combination therapy Trixeo Aerosphere (formoterol fumarate/glycopyrronium bromide/budesonide) be approved as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The recommendation, from the EMA’s Committee for Medicinal Products for…

PAO Group and Puration have entered a new agreement that will allow PAO Group to build a proprietary hemp cultivar development facility on Puration’s branded site in Farmersville, Texas, according to a press release. The new facility is expected to help provide materials to further the development of…

Synairgen‘s anti-viral therapy SNG001 has a good safety profile in people with chronic obstructive pulmonary disease (COPD), Phase 2 trial data show. The data also indicate that SNG001 induces its intended anti-viral effect, and that it improves lung function in COPD patients with viral lung infections. “These…

Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) outperformed Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe exacerbations in people with chronic obstructive pulmonary disease (COPD) during all seasons of the year, new data from the ETHOS clinical trial show. That data will be presented by…